541
Views
57
CrossRef citations to date
0
Altmetric
Review

A review of nebulized drug delivery in COPD

Pages 2585-2596 | Published online: 18 Oct 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (10)

Sagar Salave, Pranav Patel, Nimeet Desai, Dhwani Rana, Derajram Benival, Dignesh Khunt, Kasitpong Thanawuth, Bhupendra G Prajapati & Pornsak Sriamornsak. (2023) Recent advances in dosage form design for the elderly: a review. Expert Opinion on Drug Delivery 0:0, pages 1-19.
Read now
Igor Z Barjaktarevic & Aaron P Milstone. (2020) Nebulized Therapies in COPD: Past, Present, and the Future. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 1665-1677.
Read now
Collin M Clark, David M Jacobs & Sanjay Sethi. (2020) Revefenacin for the treatment of chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine 14:3, pages 239-247.
Read now
Marie T Borin, Arthur Lo, Chris N Barnes, Srikanth Pendyala & David L Bourdet. (2019) Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 2305-2318.
Read now
Bartolome R Celli, Maryam Navaie, Zhun Xu, Soojin Cho-Reyes, Carole Dembek & Todd P Gilmer. (2019) Medication management patterns among Medicare beneficiaries with chronic obstructive pulmonary disease who initiate nebulized arformoterol treatment. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 1019-1031.
Read now
Nicola A Hanania, Sanjay Sethi, Arkady Koltun, Jonathan K Ward, Jacqui Spanton & Dik Ng. (2019) Long-term safety and efficacy of formoterol fumarate inhalation solution in patients with moderate-to-severe COPD. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 117-127.
Read now
James F Donohue, Donald A Mahler & Sanjay Sethi. (2019) Revefenacin: A Once-Daily, Long-Acting Bronchodilator For Nebulized Treatment Of COPD. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 2947-2958.
Read now
Fuyuan Li & Junyi Yang. (2019) Revefenacin for the treatment of chronic obstructive pulmonary disease. Expert Review of Clinical Pharmacology 12:4, pages 293-298.
Read now
Pierachille Santus, Dejan Radovanovic, Andrea Cristiano, Vincenzo Valenti & Maurizio Rizzi. (2017) Role of nebulized glycopyrrolate in the treatment of chronic obstructive pulmonary disease. Drug Design, Development and Therapy 11, pages 3257-3271.
Read now

Articles from other publishers (47)

Sian Jones-Barry & Karen Vennard. (2023) Chronic obstructive pulmonary disease: reducing the risk of winter exacerbations. Primary Health Care.
Crossref
Junjie Su, Yangyang Zhang, Liang Cheng, Ling Zhu, Runhuai Yang, Fuzhou Niu, Ke Yang & Yuping Duan. (2023) Oribron: An Origami-Inspired Deformable Rigid Bronchoscope for Radial Support. Micromachines 14:4, pages 822.
Crossref
Svetlana N. Buynova. (2023) MODERN ASPECTS OF NEBULIZER THERAPY. Baikal Medical Journal 2:1, pages 50-59.
Crossref
Michael Troy, Joseph Van Vleet, Donald Tashkin & Igor Barjaktarevic. (2023) Recent advances predict a bright future for nebulizers. Current Opinion in Pulmonary Medicine 29:2, pages 123-132.
Crossref
BARTŁOMIEJ ROSPOND, AGATA KRAKOWSKA, BOŻENA MUSZYŃSKA & WŁODZIMIERZ OPOKA. (2022) The history, current state and perspectives of aerosol therapy. Acta Pharmaceutica 72:2, pages 225-243.
Crossref
Baofeng Liu, Shuangjiang Zan & Weishun Luo. (2022) Safety evaluation of revefenacin at the approved dose in patients with chronic obstructive pulmonary disease: A meta-analysis. Heart & Lung 52, pages 52-60.
Crossref
Qomariyatus Sholihah, Dewi Hardiningtyas, Kumoro Lenggono, Stephan Adriansyah Hulukati, Wahyudi Kuncoro & Eko Tri Wisuda. (2022) Usability Prototype Smart Portable Nebulizer for Self-care with Respiratory Disorders at Home. Open Access Macedonian Journal of Medical Sciences 10:E, pages 171-176.
Crossref
Sakshi V Khairnar, Divya D Jain, Srushti M Tambe, Yashashri R Chavan & Purnima D Amin. (2022) Nebulizer systems: a new frontier for therapeutics and targeted delivery. Therapeutic Delivery 13:1, pages 31-49.
Crossref
Glenn D. Crater, Karmon Johnson, Jonathan Ward & Jan De Backer. (2022) Lung deposition of inhaled once-daily long-acting muscarinic antagonists via standard jet nebulizer or dry powder inhaler, measured using functional respiratory imaging, in patients with chronic obstructive pulmonary disease . Therapeutic Advances in Respiratory Disease 16, pages 175346662210775.
Crossref
S.K. Katiyar, S.N. Gaur, R.N. Solanki, Nikhil Sarangdhar, J.C. Suri, Raj Kumar, G.C. Khilnani, Dhruva Chaudhary, Rupak Singla, Parvaiz A. Koul, Ashok A. Mahashur, A.G. Ghoshal, D. Behera, D.J. Christopher, Deepak Talwar, Dhiman Ganguly, H. Paramesh, K.B. Gupta, Mohan Kumar T, P.D. Motiani, P.S. Shankar, Rajesh Chawla, Randeep Guleria, S.K. Jindal, S.K. Luhadia, V.K. Arora, V.K. Vijayan, Abhishek Faye, Aditya Jindal, Amit K. Murar, Anand Jaiswal, Arunachalam M, A.K. Janmeja, Brijesh Prajapat, C. Ravindran, Debajyoti Bhattacharyya, George D'Souza, Inderpaul Singh Sehgal, J.K. Samaria, Jogesh Sarma, Lalit Singh, M.K. Sen, Mahendra K. Bainara, Mansi Gupta, Nilkanth T. Awad, Narayan Mishra, Naveed N. Shah, Neetu Jain, Prasanta R. Mohapatra, Parul Mrigpuri, Pawan Tiwari, R. Narasimhan, R. Vijai Kumar, Rajendra Prasad, Rajesh Swarnakar, Rakesh K. Chawla, Rohit Kumar, S. Chakrabarti, Sandeep Katiyar, Saurabh Mittal, Sonam Spalgais, Subhadeep Saha, Surya Kant, V.K. Singh, Vijay Hadda, Vikas Kumar, Virendra Singh, Vishal Chopra & Visweswaran B. (2022) Indian Guidelines on Nebulization Therapy. Indian Journal of Tuberculosis 69, pages S1-S191.
Crossref
Omar S Usmani. 2022. Encyclopedia of Respiratory Medicine. Encyclopedia of Respiratory Medicine 754 765 .
Chandrakantsing V. Pardeshi, Sagar R. Pardeshi & Jitendra B. Naik. 2022. Advanced Drug Delivery Strategies for Targeting Chronic Inflammatory Lung Diseases. Advanced Drug Delivery Strategies for Targeting Chronic Inflammatory Lung Diseases 219 258 .
Musalitdin A. Abdullaev, Anton I. Grechukhin, Ekaterina A. Orlova & Bela I. Kantemirova. (2021) Pharmacoeconomic Analysis of Inhalation Drugs Availability Used in COPD Treatment. Health, Food & Biotechnology 3:4.
Crossref
Xiang Wang, Zuozhou Xie, Jinhong Zhao, Zhenghua Zhu, Chen Yang & Yi Liu. (2021) Prospects of Inhaled Phage Therapy for Combatting Pulmonary Infections. Frontiers in Cellular and Infection Microbiology 11.
Crossref
Yendry Ventura-Carmenate, Fatima Mohammed Alkaabi, Yandy Marx Castillo-Aleman, Carlos Agustin Villegas-Valverde, Yasmine Maher Ahmed, Pierdanilo Sanna, Ayesha Abdulla Almarzooqi, Abeer Abdelrazik, Gina Marcela Torres-Zambrano, Maura Wade-Mateo, David Quesada-Saliba, Loubna Abdel Hadi, Antonio Alfonso Bencomo-Hernandez & Rene Antonio Rivero-Jimenez. (2021) Safety and efficacy of autologous non-hematopoietic enriched stem cell nebulization in COVID-19 patients: a randomized clinical trial, Abu Dhabi 2020. Translational Medicine Communications 6:1.
Crossref
Jiaxing Zhang, Yihong Xie, Joey Sum-wing Kwong, Long Ge, Rui He, Wenyi Zheng, Jing Han, Rui Zhang, Huaye Zhao, Yuru He & Xiaosi Li. (2021) The Efficacy and Safety of Revefenacin for the Treatment of Chronic Obstructive Pulmonary Disease: A Systematic Review. Frontiers in Pharmacology 12.
Crossref
Suyash M. Patil, Shruti S. Sawant & Nitesh K. Kunda. (2021) Inhalable bedaquiline-loaded cubosomes for the treatment of non-small cell lung cancer (NSCLC). International Journal of Pharmaceutics 607, pages 121046.
Crossref
Derek Nash. (2021) Poor Inhaler Adherence and Techniques – How Can We Improve It?. Current Geriatrics Reports 10:2, pages 66-71.
Crossref
H. Edward DavidsonPeter RadlowskiLisa HanTheresa I. ShiremanCarole DembekXiaoli NiuStefan Gravenstein. (2021) Clinical Characterization of Nursing Facility Residents With Chronic Obstructive Pulmonary Disease. The Senior Care Pharmacist 36:5, pages 248-257.
Crossref
Gamze KAŞ & Suzan YILDIZ. (2021) Çocuklarda Nebülizatör Tedavisi ve Hemşireler İçin ÖnerilerNebulizer Therapy in Children and Recommendations for Nurses. Ordu Üniversitesi Hemşirelik Çalışmaları Dergisi 4:1, pages 141-148.
Crossref
Sarah E. Petite, Michael W. Hess & Herbert Wachtel. (2020) The Role of the Pharmacist in Inhaler Selection and Education in Chronic Obstructive Pulmonary Disease. Journal of Pharmacy Technology 37:2, pages 95-106.
Crossref
Frank Li, Jiwoong Choi, Chunrui Zou, John D. NewellJr.Jr., Alejandro P. Comellas, Chang Hyun Lee, Hongseok Ko, R. Graham Barr, Eugene R. Bleecker, Christopher B. Cooper, Fereidoun Abtin, Igor Barjaktarevic, David Couper, MeiLan Han, Nadia N. Hansel, Richard E. Kanner, Robert PaineIIIIII, Ella A. Kazerooni, Fernando J. Martinez, Wanda O’Neal, Stephen I. Rennard, Benjamin M. Smith, Prescott G. Woodruff, Eric A. Hoffman & Ching-Long Lin. (2021) Latent traits of lung tissue patterns in former smokers derived by dual channel deep learning in computed tomography images. Scientific Reports 11:1.
Crossref
Ahmad Kantar. (2021) What makes flunisolide different among inhaled corticosteroids used for nebulization: a close look at the role of aqueous solubility. Multidisciplinary Respiratory Medicine 16.
Crossref
James F. Donohue, Edward Kerwin, Chris N. Barnes, Edmund J. Moran, Brett Haumann & Glenn D. Crater. (2020) Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis. BMC Pulmonary Medicine 20:1.
Crossref
Jill A. Ohar, Andrea Bauer, Sanjay Sharma & Shahin Sanjar. (2020) In Vitro Effect of Different Airflow Rates on the Aerosol Properties of Nebulized Glycopyrrolate in the eFlow® Closed System and Tiotropium Delivered in the HandiHaler®. Pulmonary Therapy 6:2, pages 289-301.
Crossref
Swetha R. PalliMonica FrazerMary DuCharmeAmi R. BuikemaAmy J. AndersonJessica Franchino-Elder. (2020) Differences in Real-World Health and Economic Outcomes Among Patients with COPD Treated with Combination Tiotropium/Olodaterol Versus Triple Therapy. Journal of Managed Care & Specialty Pharmacy 26:10, pages 1363-1374.
Crossref
António Duarte de Araújo & Jaime Correia-de-Sousa. (2020) COPD: Will There Be Room for Nebulisers After the Current COVID-19 Pandemic?. Open Respiratory Archives 2:4, pages 265-266.
Crossref
Chris N. Barnes, Donald A. Mahler, Jill A. Ohar, David A. Lombardi & Glenn D. Crater. (2020) Peak Inspiratory Flows. Chest 158:4, pages 1413-1419.
Crossref
Hosanna Brave & Ronan MacLoughlin. (2020) State of the Art Review of Cell Therapy in the Treatment of Lung Disease, and the Potential for Aerosol Delivery. International Journal of Molecular Sciences 21:17, pages 6435.
Crossref
Priya Brunsdon, Bhawana Saluja & Chandrahas Sahajwalla. (2020) Clinical Pharmacology Considerations for Developing Small‐Molecule Treatments for COVID‐19. The Journal of Clinical Pharmacology 60:9, pages 1147-1154.
Crossref
Matthew G. Macowan, Hong Liu, Marianne D. Keller, Miranda Ween, Rhys Hamon, Hai B. Tran & Sandra Hodge. (2020) Interventional low‐dose azithromycin attenuates cigarette smoke‐induced emphysema and lung inflammation in mice. Physiological Reports 8:13.
Crossref
Nardos Hailu, Michiel Postema, Ondrej Krejcar & Dawit Assefa. (2020) Nebulization Criteria and Quantification. Fluids 5:2, pages 91.
Crossref
Sean D. McCarthy, Héctor E. González & Brendan D. Higgins. (2020) Future Trends in Nebulized Therapies for Pulmonary Disease. Journal of Personalized Medicine 10:2, pages 37.
Crossref
Eusebi Chiner Vives, Estrella Fernández Fabrellas, Ramón Agüero Balbín & Miguel Ángel Martínez García. (2020) Aerosolterapia. Open Respiratory Archives 2:2, pages 89-99.
Crossref
Yuki Oiso, Tomomi Akita, Daiki Kato & Chikamasa Yamashita. (2020) Method for Pulmonary Administration Using Negative Pressure Generated by Inspiration in Mice. Pharmaceutics 12:3, pages 200.
Crossref
Sanjay Sethi, James F. Donohue, Gary T. Ferguson, Chris N. Barnes & Glenn D. Crater. (2020) Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials. Therapeutic Advances in Respiratory Disease 14, pages 175346662090527.
Crossref
Avinash Kharat, Vikrant R. Patil, Supriya Kheur & Ramesh Bhonde. (2019) Airway delivery of conditioned media from mesenchymal stem cells (MSC-CM) for COPD. Pulmonary Pharmacology & Therapeutics 58, pages 101832.
Crossref
James F. Donohue, Edward Kerwin, Sanjay Sethi, Brett Haumann, Srikanth Pendyala, Lorna Dean, Chris N. Barnes, Edmund J. Moran & Glenn Crater. (2019) Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease. Respiratory Medicine 153, pages 38-43.
Crossref
Edward M. KerwinJames F. DonohueGary T. FergusonVaidyanathan GanapathyAyca Ozol-GodfreyKrithika Rajagopalan. (2019) Satisfaction with the Use of eFlow Closed-System Nebulizer in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: Findings from a Long-Term Safety Study. Journal of Aerosol Medicine and Pulmonary Drug Delivery 32:1, pages 24-33.
Crossref
Dominique N. Price, Nitesh K. Kunda & Pavan Muttil. (2019) Challenges Associated with the Pulmonary Delivery of Therapeutic Dry Powders for Preclinical Testing. KONA Powder and Particle Journal 36:0, pages 129-144.
Crossref
Juan Carlos Vázquez-García, Rafael de Jesús Hernández-Zenteno, José Rogelio  Pérez-Padilla, María del Carmen Cano-Salas, Margarita Fernández-Vega, Jorge Salas-Hernández, Marco Antonio  Figueroa-Morales, Rosaura Esperanza  Benítez-Pérez, Luis Adrián  Rendón-Pérez, Jesús Vázquez-Cortés, Mayra Edith  Mejía-Ávila, José Luis  Mayorga-Butrón, Moisés Acuña-Kaldman,  Rocío  Barriga-Acevedo, Alma Rosa  Bizarrón-Muro, Robert  Camargo-Ángeles, Catalina  Casillas-Suárez, Celia Oralia  Castañeda-Hernández, Rafael Patricio  Castañón-Rodríguez, Juan Francisco  Castillo-Sánchez, Arturo Cortés-Télles,  Jesús Javier  Díaz-Castañón, Abelardo  Elizondo Ríos, María Guadalupe  Espitia-Hernández, Martha Angélica García-Avilés,  Rogelio  García-Torrentera, Julio Edgardo González Aguirre, Fernando Carlos  Guillén-Ortega, José Carlos  Herrera-García, Marco Antonio  Loustaunau-Andrade, Gerardo Ezequiel Magdaleno Maldonado, Luz Audina Mendoza Topete, José Padua-García,  Andrés Palomar-Lever,  Rafael Francisco  Páramo-Arroyo, Saraí del Carmen  Toral-Freyre, José Felipe  Villegas-Elizondo & Edgar Gerardo  Zozoaga-Velázquez. (2019) Guía de Práctica Clínica Mexicana para el diagnóstico y tratamiento de la Enfermedad Pulmonar Obstructiva Crónica <br>GUÍA MEXICANA DE EPOC, 2020. NCT Neumología y Cirugía de Tórax 78:S1, pages 4-76.
Crossref
Dean Quinn, Christopher N. Barnes, Wayne Yates, David L. Bourdet, Edmund J. Moran, Peter Potgieter, Andrew Nicholls, Brett Haumann & Dave Singh. (2018) Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies. Pulmonary Pharmacology & Therapeutics 48, pages 71-79.
Crossref
Stephan Ehrmann. (2018) Vibrating Mesh Nebulisers – Can Greater Drug Delivery to the Airways and Lungs Improve Respiratory Outcomes?. European Respiratory & Pulmonary Diseases 4:1, pages 33.
Crossref
Alan Kaplan & David Price. (2018) Matching Inhaler Devices with Patients: The Role of the Primary Care Physician. Canadian Respiratory Journal 2018, pages 1-9.
Crossref
Krishna K. Pudi, Chris N. Barnes, Edmund J. Moran, Brett Haumann & Edward Kerwin. (2017) A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease. Respiratory Research 18:1.
Crossref
Gary T. Ferguson, Thomas Goodin, Robert Tosiello, Alistair Wheeler & Edward Kerwin. (2017) Long-term safety of glycopyrrolate/eFlow® CS in moderate-to-very-severe COPD: Results from the Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer (GOLDEN) 5 randomized study. Respiratory Medicine 132, pages 251-260.
Crossref
Edward Kerwin, James F. Donohue, Thomas Goodin, Robert Tosiello, Alistair Wheeler & Gary T. Ferguson. (2017) Efficacy and safety of glycopyrrolate/eFlow® CS (nebulized glycopyrrolate) in moderate-to-very-severe COPD: Results from the glycopyrrolate for obstructive lung disease via electronic nebulizer (GOLDEN) 3 and 4 randomized controlled trials. Respiratory Medicine 132, pages 238-250.
Crossref